Prostate Cancer - Results from #900

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer. July 3, 2024

Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer. July 3, 2024

A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer. July 3, 2024

Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study. July 3, 2024

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. July 3, 2024

U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer July 2, 2024

PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease? July 2, 2024

Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis. July 2, 2024

Reducing Racial Inequalities in Prostate Cancer Treatment: Healthcare Access Barriers. July 2, 2024

Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting. July 2, 2024

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D. July 2, 2024

RECOVERY OF SOCIAL CONTINENCE AND SEXUAL FUNCTION IN MEN WITH HIGH-RISK PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: RESULTS FROM A STATEWIDE COLLABORATIVE. July 1, 2024

Updates to Incontinence After Prostate Treatment: AUA/GURS/SUFU Guideline (2024). July 1, 2024

Negative biopsy histology in men with PI-RADS score 5: is it useful PSMA PET/CT evaluation? July 1, 2024

Should systematic prostatic biopsies be discontinued? July 1, 2024

Assessment of PSA responses and changes in the rate of tumor growth (g-rate) with immune checkpoint inhibitors in US Veterans with prostate cancer. July 1, 2024

Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer A Systematic Review and Meta-Analysis June 28, 2024

ChatGPT can help guide and empower patients after prostate cancer diagnosis. June 28, 2024

Image-guided multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes. June 28, 2024

Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer. June 28, 2024

Page 46 of 1447